Wikidata entity: Q64804467
Quantities
| P4135 | maximum age | 85 |
| P2899 | minimum age | 50 |
| P1132 | number of participants | 182 |
| P6099 | clinical trial phase | ... | Q42824440 (phase II clinical trial) | phase II clinical trial |
| P17 | country | ... | Q17 (Japan) | Japan |
| P17 | country | ... | Q29 (Spain) | Spain |
| P17 | country | ... | Q30 (United States) | United States |
| P17 | country | ... | Q38 (Italy) | Italy |
| P17 | country | ... | Q142 (France) | France |
| P17 | country | ... | Q145 (United Kingdom) | United Kingdom |
| P17 | country | ... | Q183 (Germany) | Germany |
| P582 | end time | ... | 2020-03-11 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1050 | medical condition | ... | Q83030 (dementia) | dementia |
| P6153 | research site | ... | Q230492 (University of Michigan) | University of Michigan |
| P6153 | research site | ... | Q49088 (Columbia University) | Columbia University |
| P6153 | research site | ... | Q30270033 (PMG Research) | PMG Research |
| P580 | start time | ... | 2018-05-04 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | ??? |
| P3098 | ClinicalTrials.gov ID | NCT03467152 |
Why not click here or view trends?
log id: 5813802